drugset / Trial / NCT05009290
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).
Timeline
- Start
- 2021-11-01
- Primary completion
- 2024-09-06
- Completion
- 2024-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezvilutamide | Small molecule | 240 mg | Oral |
Indications
No indication recorded.